Vaccination of a B16-Ova melanoma with recombinant, OVA-expressing TMEV resulted in a robust antigen-restricted CD8+ T cell response corresponding to a delay in tumor growth and improved survival[21]. The gene discussed is CD8A; the disease is neoplasm.